Cargando…
Anti–SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report
Autores principales: | Boongird, Sarinya, Chuengsaman, Piyatida, Phanprasert, Salinnart, Kitpermkiat, Rungthiwa, Assanatham, Montira, Nongnuch, Arkom, Kiertiburanakul, Sasisopin, Malathum, Kumthorn, Phuphuakrat, Angsana, Setthaudom, Chavachol, Bruminhent, Jackrapong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society of Nephrology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375247/ https://www.ncbi.nlm.nih.gov/pubmed/34419552 http://dx.doi.org/10.1016/j.kint.2021.08.007 |
Ejemplares similares
-
Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine
por: Boongird, Sarinya, et al.
Publicado: (2021) -
Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)
por: Boongird, Sarinya, et al.
Publicado: (2022) -
Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients
por: Bruminhent, Jackrapong, et al.
Publicado: (2022) -
SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study)
por: Bruminhent, Jackrapong, et al.
Publicado: (2022) -
494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period
por: Rojanakit, Gun, et al.
Publicado: (2023)